Business Context and Reporting Period
Company: Aytu BioScience, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 2, 2018
Reporting Period: Event-based report covering agreements entered into on November 2, 2018, and disclosures made on November 5, 2018.
Key Financial Metrics and Agreements
This filing does not report historical revenue, profit, cash flow, or margin data. It details the following financial commitments and transactions:
- License Agreement: Entered into a License, Development, Manufacturing, and Supply Agreement with TRIS Pharma, Inc. for exclusive U.S. rights to Tuzistra XR and a complementary antitussive (CCP-08).
- Consideration Paid: The Company made an upfront cash payment and issued shares of Series D Convertible Preferred Stock to TRIS. Specific dollar amounts for the cash payment and stock issuance are not disclosed in this text.
- Future Obligations: The Company is obligated to pay milestone payments and royalty fees to TRIS.
- Proposed Financing: The Company expects to issue a secured, non-convertible note (the "Armistice Note") to Armistice Capital for up to $5 million.
- Note Terms: Expected annual interest rate of 8%, three-year term, secured by future revenue from the Products, with principal and interest payable at maturity.
Material Changes
The filing reports a material strategic shift through the acquisition of exclusive U.S. licenses for two pharmaceutical products (Tuzistra XR and CCP-08). This represents a significant change in the Company's product portfolio and future revenue streams compared to the prior period, contingent upon the successful marketing approval of CCP-08 by the FDA.
Guidance, Outlook, and Risks
- Outlook: Management intends to use the Armistice Note to support continued growth. The Company expects to close the note on or around November 13, 2018.
- Repayment Flexibility: The Company expects to have the right to repay the Armistice Note at any time without penalty, 30 days following the closing.
- Risks and Contingencies:
- The Agreement with TRIS may be terminated by either party upon a material breach.
- The CCP-08 product has not yet received marketing approval; the license is contingent on the New Drug Application filed with the FDA.
- Certain terms of the Agreement are subject to confidential treatment and will be filed later in the Form 10-Q.
- Forward-looking statements regarding operating results and performance are subject to substantial risks and uncertainties.
Investor Verification Checklist
- Verify the exact amount of the upfront cash payment and the number of Series D Convertible Preferred Stock shares issued to TRIS (not disclosed in this 8-K).
- Confirm the status of the FDA New Drug Application for CCP-08 and the likelihood of approval.
- Review the full text of the License Agreement once filed as an exhibit to the Form 10-Q for the quarter ending December 31, 2018, to understand confidential terms.
- Monitor the closing of the $5 million Armistice Note and confirm the final interest rate and security terms.
- Assess the Company's existing debt load and liquidity position to determine the impact of the new note and royalty obligations.